NorthWest Biotherapeutics Inc (NWBO)

[LessIsMore]

Press Release: Northwest Biotherapeutics (OTCQB:NWBO) Further Expands Senior Management Team

BETHESDA, Md., Dec. 12, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax(R) personalized immune therapies for solid tumor cancers, today announced that it has further expanded its senior management team with the addition of Ms. Jean M. Davis as Chief Financial Officer, Chief Accounting Officer, and interim Chief Information Officer.

Ms. Davis comes to NW Bio from BDO USA LLP, where she was a Risk Advisory Senior Manager. She is a Certified Public Accountant, Certified Sarbanes-Oxley Expert, Certified Internal Auditor, and Certified Project Management Professional. She obtained her Master of Science in Business with a concentration in Finance and Accounting from Johns Hopkins University.

Ms. Davis brings over 24 years of experience assisting both national and multi-national, public and private companies with their finance and accounting functions, financial reporting, compliance with financial, industry-specific and federal regulations, and related matters. Ms. Davis also worked previously at Deloitte & Touche.

"We are delighted to welcome Ms. Davis to NW Bio," commented NW Bio's CEO, Linda Powers. "We believe that her breath of knowledge and experience in finance and accounting, project management, data analytics and information technology, as well as her passion for our cause with DCVax(R), will make Ms. Davis a strong addition to the NW Bio executive team."

Ms. Davis commented: "NW Bio is pursuing an exciting cause with its novel DCVax(R) immune therapies for cancer. I look forward to bringing my background and experience to bear to help take the Company to the next level.